Immediate eradication of Helicobacter pylori in patients with previously documented peptic ulcer disease : Clinical and economic effects.
The clinical and economic benefits of Helicobacter pylori eradication for patients with newly diagnosed peptic ulcer disease are widely accepted.
The objective of this study was to estimate the cost-effectiveness of H. pylori eradication in the large cohort of asymptomatic patients receiving maintenance antisecretory therapy for a previously documented peptic ulcer disease.
A decision analytic model estimated the clinical and economic effects of two management strategies for asymptomatic patients receiving maintenance antisecretory therapy for a previously documented peptic ulcer : strategy 1-immediate H. pylori eradication therapy and cessation of maintenance therapy, and strategy 2-continued-maintenance antisecretory therapy, with H. pylori eradication therapy reserved for the first symptom recurrence.
At 1 yr, the model estimated that immediate H. pylori eradication therapy (strategy 1) led to 22% fewer months with ulcers (28.7 vs. 36.8 ulcer months/100 patient years), 10% fewer months with ulcer symptoms (21.0 vs. 23.1 symptom months/100 patient years), and 24% lower per-patient expenditures ($587 vs. $767/patient year) than maintenance antisecretory therapy and symptom-based H. pytori eradication (strategy 2).
Immediate H. pylori eradication, however, resulted in 14% more months with upper gastrointestinal symptoms from all causes (37.9 vs. 33. (...)
Mots-clés Pascal : Ulcère, Gastroduodénal, Complication, Gastrite, Campylobactériose, Bactériose, Infection, Helicobacter pylori, Spirillaceae, Spirillales, Bactérie, Effet biologique, Eradication, Evolution, Coût, Etude statistique, Homme, Appareil digestif pathologie, Estomac pathologie, Intestin pathologie, Economie santé
Mots-clés Pascal anglais : Ulcer, Gastroduodenal, Complication, Gastritis, Campylobacter infection, Bacteriosis, Infection, Helicobacter pylori, Spirillaceae, Spirillales, Bacteria, Biological effect, Eradication, Evolution, Costs, Statistical study, Human, Digestive diseases, Gastric disease, Intestinal disease, Health economy
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 98-0007322
Code Inist : 002B05B02F. Création : 17/04/1998.